Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment.

SETTING Cross-sectional study at four out-patient clinics in a single referral centre in Italy. OBJECTIVE To evaluate the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) in human immunodeficiency virus (HIV) infected adults and in patients with immune-mediated inflammatory diseases (IMIDs) who are candidates for anti-tumour necrosis factor-alpha (TNF-alpha) treatment. DESIGN A total of 402 immunocompromised patients were enrolled, including 207 HIV-infected individuals and 195 IMID patients scheduled for anti-TNF-alpha treatment. Tuberculin skin test (TST) and QFT-GIT were performed. For active tuberculosis (TB), test results were compared with microbiological, histopathological and clinical diagnoses. RESULTS In HIV-infected patients, the level of agreement between the tests was 68% and QFT-GIT sensitivity was 66% (95%CI 47-82). We found a large proportion of indeterminate QFT-GIT results (33.4%), which correlated with CD4 count < 200 cells/microl (P < 0.0001). The degree of agreement with TST was higher in IMID patients (81.6%). Factors associated with discordant positive TST and negative QFT-GIT results were bacille Calmette-Guérin vaccination (P = 0.0001), previous TB (P = 0.0001) and agricultural work (P = 0.0005). CONCLUSION The performance of QFT-GIT varies between different types of immunocompromised patients. Interferon-gamma release assays should not be used to confirm or rule out a diagnosis of active TB in HIV-infected adults. As there were no cases of active TB in the IMID subgroup, it was difficult to determine which test performs better in this population.

[1]  U. Arad,et al.  QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  L. Fabbri,et al.  Performance of tests for latent tuberculosis in different groups of immunocompromised patients. , 2009, Chest.

[3]  F. Drobniewski,et al.  Interferon-γ release assays for the diagnosis of active tuberculosis: sensible or silly? , 2009, European Respiratory Journal.

[4]  I. Latorre,et al.  IFN-γ-release assays to diagnose TB infection in the immunocompromised individual , 2009, Expert review of respiratory medicine.

[5]  V. Vullo,et al.  In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon-γ T Cell Response , 2009, PloS one.

[6]  M. Cerinic,et al.  QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases , 2009, European Respiratory Journal.

[7]  V. Vullo,et al.  QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. , 2008, Diagnostic microbiology and infectious disease.

[8]  S. Staszewski,et al.  Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country , 2008, AIDS.

[9]  Madhukar Pai,et al.  Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.

[10]  D. Vassilopoulos,et al.  Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. , 2008, The Journal of rheumatology.

[11]  B. Bresnihan,et al.  Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies , 2008, Current opinion in rheumatology.

[12]  N. Balato,et al.  Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  S. Abramson,et al.  Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. , 2008, The Journal of rheumatology.

[14]  E. Acevedo-Vásquez,et al.  Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. , 2008, The Journal of rheumatology.

[15]  A. Gurtman,et al.  Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  P. Villiger,et al.  Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay , 2007, Annals of the rheumatic diseases.

[17]  A. Lalvani.  Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. , 2007, Chest.

[18]  Jeffrey N. Martin,et al.  Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals , 2007 .

[19]  M. Pai,et al.  Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research , 2007, Annals of Internal Medicine.

[20]  T. Schaeverbeke,et al.  Role of anti-tumour necrosis factor-α therapeutic agents in the emergence of infections , 2006 .

[21]  P. Ravn,et al.  Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon-γ test , 2006, Respiratory research.

[22]  L. Lambert,et al.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  B. Metchock,et al.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[24]  M. Johnson,et al.  Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count , 2005, AIDS.

[25]  P. Francioli,et al.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[27]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[28]  R. Huebner,et al.  The tuberculin skin test. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.